AP NEWS

The Corporate Reputation of Pharma Industry - The Patient Perspective in 2017 - Global Edition - ResearchAndMarkets.com

July 31, 2018

DUBLIN--(BUSINESS WIRE)--Jul 31, 2018--The “The Corporate Reputation of Pharma Industry - The Patient Perspective in 2017 - Global Edition” report has been added to ResearchAndMarkets.com’s offering.

The ‘Corporate Reputation of Pharma in 2017’ report is based on the findings of a PatientView November 2017-February 2018 survey exploring the views of 1,330 patient groups worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2017, as well as on the performance of 46 pharma companies at 12 key indicators that influence corporate reputation.

Respondent patient groups were far more negative in 2017 than in 2016 about several other pharma-industry activities. For instance, only 48% of 2017′s respondent patient groups judged pharma Excellent or Good at being innovative. The 2017 figure is the lowest-reported percentage for the pharma industry’s capacity to innovate since 2011. Equally negative were 2017 attitudes towards the industry’s ability to make high-quality products. Only 57% of respondent patient groups in 2017 saw pharma as Excellent or Good at making high-quality products.

Major structural issues appear to be damaging the pharma industry’s R&D productivity. For example, companies are increasingly finding difficulty in differentiating their products from those of their competitors and they are also having trouble tackling unmet patient needs, and innovating. Although 2017 unlike previous years brought few, if any, large-scale safety problems, safety remains a perennial concern for most patient groups. Mental-health patient groups which represent the largest proportion of respondents to the Corporate-Reputation survey (8% in 2017) particularly emphasise the subject of patient safety.

Companies Mentioned

AbbVie Acorda Therapeutics Allergan Almirall Amgen Astellas Pharma AstraZeneca Bayer Bial Biogen Boehringer-Ingelheim Bristol-Myers Squibb Celgene Chiesi Farmaceutici CSL Behring Daiichi Sankyo Eisai Eli Lilly (Lilly) Ferring Gedeon Richter Gilead Sciences Grifols Grünenthal GSK Ipsen Janssen (Pharmaceutical Companies of Johnson & Johnson) LEO Pharma Lundbeck Menarini Merck & Co Merck KGaA Novartis Novo Nordisk Octapharma

Key Topics Covered:

1. Executive Summary

2. Methodology

3. Patient-Group Relationships With Pharma, 2017

4. Industry-Wide Findings, 2017

5. Rankings Of The 46 Pharma Companies, 2017 V. 2016 Among Patient Groups Familiar With The Companies

6. Positioning Of The 46 Pharma Companies, 2017 V. 2016 Among Patient Groups That Work/Partner With The Companies

7. Profiles Of The 46 Companies, 2017

8. Appendices

For more information about this report visit https://www.researchandmarkets.com/research/b73tk7/the_corporate?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180731005508/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Pharmaceuticals

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL COMMUNICATIONS PUBLIC RELATIONS/INVESTOR RELATIONS

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/31/2018 08:00 AM/DISC: 07/31/2018 08:01 AM

http://www.businesswire.com/news/home/20180731005508/en

AP RADIO
Update hourly